ArticleAnnals of neurology2020
Fine-Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies.
Article in Annals of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 63 citations in OpenAlex.
- A Multi-Locus and Machine Learning-Based Assessment of SNCA Variants in Alzheimer's Disease.International journal of molecular sciences · 2026Article
- Exercise Intervention for REM Sleep Behavior Disorder in Parkinson's Disease: Mechanisms and Implications for Neurorehabilitation.CNS neuroscience & therapeutics · 2026Review
- Parkinson DiseaseNeurology. Genetics · 2025Article
- Genome-wide association study of REM sleep behavior disorder in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Imaging advances to detect non-motor prodromal markers of Parkinson's disease and explore therapeutic translation opportunities.NPJ Parkinson's disease · 2025Review
- Plasma pTau181 and amyloid markers predict conversion to dementia in idiopathic REM sleep behaviour disorder.Brain : a journal of neurology · 2025Article
- GWAS by Subtraction to Disentangle RBD Genetic Background from α-Synucleinopathies.International journal of molecular sciences · 2025Article
- Gene Polymorphisms of Parkinson's Disease Risk Locus and Idiopathic REM Sleep Behavior Disorder.Biomedicines · 2025Article
- From mechanisms to future therapy: a synopsis of isolated REM sleep behavior disorder as early synuclein-related disease.Molecular neurodegeneration · 2025Review
- Factors associated with phenoconversion of idiopathic rapid eye movement sleep behavior disorder: a prospective study.NPJ Parkinson's disease · 2025Article
- Lack of epistatic interaction ofBrain communications · 2025Article
- Longitudinal decline in DAT binding in Parkinson's disease: connections with sleep disturbances.BMC medicine · 2024Article
- Non-motor symptoms of Parkinson`s disease-insights from genetics.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Approaches to Early Parkinson's Disease Subtyping.Journal of Parkinson's disease · 2024Review
- Investigation of the genetic aetiology of Lewy body diseases with and without dementia.Brain communications · 2024Article
- Investigation of the genetic aetiology of Lewy body diseases with and without dementia.medRxiv : the preprint server for health sciences · 2023Article
- Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects.Nature communications · 2022Article
- Rapid eye movement sleep behaviour disorder: Past, present, and future.Journal of sleep research · 2022Review
- Clinical Sphingolipids Pathway in Parkinson's Disease: From GCase to Integrated-Biomarker Discovery.Cells · 2022Review
- Predictors of RBD progression and conversion to synucleinopathies.Current neurology and neuroscience reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
51 authors at 20 institutions in 9 countries.
Funding
Abstract
objectiveRapid eye movement sleep behavior disorder (RBD) is a prodromal synucleinopathy, as >80% will eventually convert to overt synucleinopathy. We performed an in-depth analysis of the SNCA locus to identify RBD-specific risk variants.
methodsFull sequencing and genotyping of SNCA was performed in isolated/idiopathic RBD (iRBD, n = 1,076), Parkinson disease (PD, n = 1,013), dementia with Lewy bodies (DLB, n = 415), and control subjects (n = 6,155). The iRBD cases were diagnosed with RBD prior to neurodegeneration, although some have since converted. A replication cohort from 23andMe of PD patients with probable RBD (pRBD) was also analyzed (n = 1,782 cases; n = 131,250 controls). Adjusted logistic regression models and meta-analyses were performed. Effects on conversion rate were analyzed in 432 RBD patients with available data using Kaplan-Meier survival analysis.
resultsA 5'-region SNCA variant (rs10005233) was associated with iRBD (odds ratio [OR] = 1.43, p = 1.1E-08), which was replicated in pRBD. This variant is in linkage disequilibrium (LD) with other 5' risk variants across the different synucleinopathies. An independent iRBD-specific suggestive association (rs11732740) was detected at the 3' of SNCA (OR = 1.32, p = 4.7E-04, not statistically significant after Bonferroni correction). Homozygous carriers of both iRBD-specific SNPs were at highly increased risk for iRBD (OR = 5.74, p = 2E-06). The known top PD-associated variant (3' variant rs356182) had an opposite direction of effect in iRBD compared to PD.
interpretationThere is a distinct pattern of association at the SNCA locus in RBD as compared to PD, with an opposite direction of effect at the 3' of SNCA. Several 5' SNCA variants are associated with iRBD and with pRBD in overt synucleinopathies. ANN NEUROL 2020;87:584-598.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.